More information
Description
The main aim of the project is the R&D of novel radiopharmaceuticals based on terbium-161 and novel vectors for targeted therapy of tumors. The advantage of Tb-161 is in the emission of large numbers of low energy electrons followed by gamma radiation allowing tomographic imaging and therapy follow-up. This will allow targeting of single cancer cells, micrometastases and whole tumors, particularly in early stages of diseases to increase the treatment efficiency. Project results include not only the Tb-161 production in relevant quantity, but also novel targeting molecules (see project results). Collaboration between the Czech and Norway highly experienced partners in the research, development and commercialization of the results has all prerequisites to reach the proposed results.
Summary of project results
The project aimed to address the need for more efficient and targeted cancer therapies. Existing treatments often have limitations in reaching and destroying all cancer cells, particularly in early stages.
The project focused on the research and development of novel radiopharmaceuticals using Terbium-161 for targeted cancer therapy and diagnosis. This involved setting up production facilities for Terbium-161 in Czechia and Norway, developing and testing labeling protocols and quality control methods, producing Terbium-161 in sufficient quantities for experiments and conducting in vitro and in vivo studies to evaluate the efficacy and safety of the new radiopharmaceuticals.
The project achieved several significant results:
- Successful production of Terbium-161 in quantities exceeding the initial target.
- Development of various Terbium-161 labeled compounds for targeted cancer therapy.
- Demonstration of the potential of Terbium-161 for treating various types of cancer.
The results of the project are significant for further development and research, preclinical and clinical trials, just as they can be provided comemrcially. The resutls will have impact on cancer patients, with its potential to lead to more effective and less toxic cancer treatments.
The project has generated new knowledge and tools for the development of radiopharmaceuticals and has strengthened the research and development capabilities of both Czechia and Norway in the field of nuclear medicine.
Summary of bilateral results
The project would not have been successful without bilateral cooperation. Mutual collaboration on joint results has strengthened the knowledge of all involved entities and strengthened the bilateral cooperation which is planning to continue the experiments, two possible collaborations with foreign partners are under discussion. Project proposals are already being prepared, and plans are underway for production together.